Finally, PI4KIIIα inhibition decreased pAKT levels by decreasing PIP3 PM levels in breast cancer cells; hence, it can act in KRAS-mutant cells as a target to simultaneously inhibit both MAPK and PI3K pathways, which is an attractive notion given that 93% of PIK3CA mutations in PDAC co-occur with KRAS mutations (Park et al, 2017; Waters & Der, 2018). This evidence concerns the gene KRAS and breast carcinoma.